Condition: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Sponsor: VA Office of Research and Development
People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax. The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.
This description comes directly from the study's public registry record.
Suman Kambhampati, MD MBBS · (816) 922-2755 · suman.kambhampati@va.gov
Murali K Nittala, MBBS MS MD · (816) 861-4700 · murali.nittala@va.gov
Always discuss trial participation with your own doctor first.
| San Francisco VA Medical Center, San Francisco, CA | San Francisco, California, United States | Recruiting |
| Kansas City VA Medical Center, Kansas City, MO | Kansas City, Missouri, United States | Recruiting |
| Durham VA Medical Center, Durham, NC | Durham, North Carolina, United States | Recruiting |
| VA Puget Sound Health Care System Seattle Division, Seattle, WA | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06520098